Research
Hormonal
Tirzepatide 15 mg once weekly is preferred for individuals with obesity and prediabetes when greater weight loss is needed, achieving a 94% risk reduction in diabetes progression over 72 weeks.
If you have obesity and prediabetes, tirzepatide 15 mg once weekly is a preferred treatment to significantly reduce your risk of developing type 2 diabetes and achieve substantial weight loss, especially if lifestyle changes alone are not enough.
StrongSupportsVERY_HIGH confidence
Tirzepatide should be preferred in people with obesity and prediabetes, when greater weight loss is needed. In SURMOUNT-1, tirzepatide 15 mg OW achieved 22.5% mean Weight loss and a 94% risk reduction in diabetes progression over 72 weeks in participants with prediabetes [2].
Why this rating
Based on phase III randomized controlled trials (SURMOUNT-1) with prespecified endpoints.
Source
Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan
Dario Tuccinardi et al. · Journal of Endocrinological Investigation · 2025
narrative_reviewCited 9×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →